

# Michael L Friedlander

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5500656/michael-l-friedlander-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

308 papers	24,553 citations	65 h-index	154 g-index
329 ext. papers	29,412 ext. citations	6.4 avg, IF	6.45 L-index

#	Paper	IF	Citations
308	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. <i>Lancet, The</i> , <b>2010</b> , 376, 235-44	40	1395
307	Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1382-92	59.2	1265
306	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 244-50	2.2	1171
305	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 317, 2402-2416	27.4	1140
304	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. <i>Lancet, The</i> , <b>2010</b> , 376, 245-51	40	1089
303	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2495-2505	59.2	1061
302	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 852-61	21.7	1007
301	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1274-1284	21.7	913
300	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , <b>2011</b> , 11, 719-25	31.3	893
299	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , <b>2015</b> , 521, 489-94	50.4	890
298	BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2654-63	2.2	810
297	Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1419-25	2.2	547
296	Chemotherapy-induced peripheral neurotoxicity: a critical analysis. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2013</b> , 63, 419-37	220.7	410
295	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 87-97	21.7	405
294	Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIg). <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 419-23	3.5	400
293	Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. <i>Cytometry</i> , <b>1985</b> , 6, 327-33		394
292	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 372-9	2.2	381

291	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2403-2415	59.2	334
290	Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 1579-1589	21.7	296
289	2010 Gynecologic Cancer InterGroup (GCIg) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 750-5	3.5	292
288	Obesity and outcomes in premenopausal and postmenopausal breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2005</b> , 14, 1686-91	4	253
287	Incorporation of pazopanib in maintenance therapy of ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3374-82	2.2	245
286	Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. <i>Nature Genetics</i> , <b>2000</b> , 24, 197-200	36.3	224
285	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003212	6	209
284	A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , <b>2010</b> , 119, 32-7	4.9	199
283	"Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?. <i>Gynecologic Oncology</i> , <b>2014</b> , 133, 624-31	4.9	197
282	Secondary Somatic Mutations Restoring and Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , <b>2017</b> , 7, 984-998	24.4	193
281	Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. <i>Gynecologic Oncology</i> , <b>2016</b> , 140, 199-203	4.9	188
280	IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 2538-48	12.9	182
279	The Y deletion gr/gr and susceptibility to testicular germ cell tumor. <i>American Journal of Human Genetics</i> , <b>2005</b> , 77, 1034-43	11	172
278	Oxaliplatin-induced neurotoxicity and the development of neuropathy. <i>Muscle and Nerve</i> , <b>2005</b> , 32, 51-60	9.4	170
277	The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 116, 215-23	4.4	168
276	Guidelines for the Treatment of Recurrent and Metastatic Cervical Cancer. <i>Oncologist</i> , <b>2002</b> , 7, 342-347	5.7	162
275	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. <i>Brain</i> , <b>2009</b> , 132, 2712-23	11.2	155
274	Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. <i>Oncologist</i> , <b>2011</b> , 16, 708-16	5.7	148

273	Clinical trials in recurrent ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 771-5	3.5	147
272	It's now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer—an Australian fertility decision aid collaborative group study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1670-7	2.2	141
271	The importance of patient-reported outcomes in clinical trials and strategies for future optimization. <i>Patient Related Outcome Measures</i> , <b>2018</b> , 9, 353-367	2.9	129
270	Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1315-27	2.2	128
269	Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1309-16	2.2	127
268	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. <i>Human Molecular Genetics</i> , <b>2006</b> , 15, 443-51	5.6	127
267	Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1243-9	2.2	125
266	The fertility- and menopause-related information needs of younger women with a diagnosis of breast cancer: a qualitative study. <i>Psycho-Oncology</i> , <b>2003</b> , 12, 500-11	3.9	120
265	Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3091-9	2.2	118
264	Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 19-26	2.2	116
263	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , <b>2018</b> , 143 Suppl 2, 59-78	4	116
262	Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 2250-7	2.2	104
261	Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5485-93	12.9	103
260	Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1805-12	2.2	99
259	Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4679-86	2.2	95
258	Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 1126-1134	21.7	91
257	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , <b>2012</b> , 119 Suppl 2, S118-29	4	88
256	Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1075-1085	8.7	86

255	Uterine papillary serous carcinoma. A clinical study. <i>Cancer</i> , <b>1995</b> , 75, 2239-43	6.4	81
254	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1269-1282	21.7	80
253	The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. <i>Human Reproduction</i> , <b>2017</b> , 32, 1033-1045	5.7	79
252	Caring for women with ovarian cancer in the last year of life: a longitudinal study of caregiver quality of life, distress and unmet needs. <i>Gynecologic Oncology</i> , <b>2014</b> , 132, 690-7	4.9	78
251	Impact of oxaliplatin-induced neuropathy: a patient perspective. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 2959-67	3.9	76
250	If I am in the mood, I enjoy it: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer. <i>Oncologist</i> , <b>2011</b> , 16, 1333-44	5.7	75
249	The role of BRCA mutation testing in determining breast cancer therapy. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 7, 708-17	19.4	74
248	LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. <i>Cancer Research</i> , <b>2012</b> , 72, 4060-73	10.1	73
247	10-year performance of four models of breast cancer risk: a validation study. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 504-517	21.7	73
246	Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. <i>Human Reproduction</i> , <b>2016</b> , 31, 1126-32	5.7	72
245	Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. <i>BMC Cancer</i> , <b>2006</b> , 6, 240	4.8	69
244	Oxaliplatin and axonal Na <sup>+</sup> channel function in vivo. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4481-4	12.9	68
243	Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. <i>Gynecologic Oncology</i> , <b>1999</b> , 75, 122-9	4.9	65
242	Guidelines for the treatment of recurrent and metastatic cervical cancer. <i>Oncologist</i> , <b>2002</b> , 7, 342-7	5.7	64
241	Current management of epithelial ovarian carcinoma: a review. <i>Journal of Surgical Oncology</i> , <b>2000</b> , 19, 11-9		63
240	Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. <i>Cancer</i> , <b>2016</b> , 122, 1844-52	6.4	62
239	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , <b>2015</b> , 131 Suppl 2, S111-22	4	61
238	Prognosis of premenopausal breast cancer and childbirth prior to diagnosis. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 699-705	2.2	58

237	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 620-631	21.7	58
236	Dose effects of oxaliplatin on persistent and transient Na <sup>+</sup> conductances and the development of neurotoxicity. <i>PLoS ONE</i> , <b>2011</b> , 6, e18469	3.7	57
235	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , <b>2018</b> , 4, 522-528	13.4	56
234	Outcomes and endpoints in cancer trials: bridging the divide. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, e43-52	21.7	56
233	What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?. <i>Lancet Oncology, The</i> , <b>2005</b> , 6, 581-8	21.7	55
232	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 6002-6002	2.2	54
231	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1306-1315	21.7	52
230	Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. <i>Muscle and Nerve</i> , <b>2011</b> , 43, 367-74	3.4	52
229	The experience of cancer-related fatigue and chronic fatigue syndrome: a qualitative and comparative study. <i>Journal of Pain and Symptom Management</i> , <b>2007</b> , 34, 126-35	4.8	50
228	Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 1313-1320	8.7	47
227	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 569-580	12.9	46
226	Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials. <i>International Journal of Gynecological Cancer</i> , <b>2016</b> , 26, 648-54	3.5	46
225	Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change. <i>International Journal of Gynecological Cancer</i> , <b>2010</b> , 20, 664-84	3.5	46
224	Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. <i>Familial Cancer</i> , <b>2005</b> , 4, 105-13	3	46
223	Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. <i>Medical Journal of Australia</i> , <b>2014</b> , 201, 283-8	4	44
222	Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2000</b> , 59, 101-11	4.4	44
221	Improving cancer outcomes through international collaboration in academic cancer treatment trials. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5109-14	2.2	42
220	Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5001-5001	2.2	42



219	BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. <i>Gynecologic Oncology</i> , <b>2016</b> , 140, 443-9	4.9	41
218	Prevalence and predictors of insomnia in women with invasive ovarian cancer: anxiety a major factor. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 3262-70	7.5	39
217	The impact of aromatase inhibitors on sexual functioning: current knowledge and future research directions. <i>Breast</i> , <b>2008</b> , 17, 436-40	3.6	38
216	The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data. <i>Cancer</i> , <b>2001</b> , 92, 440-5	6.4	38
215	Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. <i>Breast Cancer Research</i> , <b>2008</b> , 10, 216	8.3	37
214	Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations. <i>Genes Chromosomes and Cancer</i> , <b>1997</b> , 18, 75-83	5	36
213	Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3920-5	2.2	35
212	Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers. <i>Medical Journal of Australia</i> , <b>2013</b> , 199, 680-3	4	35
211	Development and pilot testing of a fertility decision aid for young women diagnosed with early breast cancer. <i>Breast Journal</i> , <b>2011</b> , 17, 112-4	1.2	35
210	The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2010</b> , 28, 492-9	2.8	35
209	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , <b>2020</b> , 22, 1653-1666	8.1	34
208	Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing. <i>Oncology Nursing Forum</i> , <b>2013</b> , 40, 275-83	1.7	32
207	Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA5503-LBA5503	2.2	32
206	Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5501-5501	2.2	32
205	Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. <i>Genes Chromosomes and Cancer</i> , <b>2008</b> , 47, 247-52	5	31
204	A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy. <i>Therapeutic Advances in Medical Oncology</i> , <b>2017</b> , 9, 269-285	5.4	30
203	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors <b>2020</b> , 8,		30
202	The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. <i>Quality of Life Research</i> , <b>2016</b> , 25, 2457-2465	3.7	30

201	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. <i>Future Oncology</i> , <b>2017</b> , 13, 307-320	3.6	30
200	Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 6, 146-51	3.8	30
199	Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue. <i>Journal of Pain and Symptom Management</i> , <b>2017</b> , 54, 74-84	4.8	29
198	Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2017</b> , 41, 126-138	4.6	29
197	Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1721-1731	21.7	29
196	Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3528-3537	2.2	29
195	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2140-2150	2.2	28
194	Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. <i>Gynecologic Oncology</i> , <b>2015</b> , 136, 18-24	4.9	28
193	Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma. <i>Gynecologic Oncology</i> , <b>2007</b> , 106, 44-51	4.9	28
192	Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 6, 297-304	3.8	27
191	Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2362	2.2	25
190	The role of hormonal therapy in gynecological cancers-current status and future directions. <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 1328-33	3.5	25
189	Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2009</b> , 18, 1792-7	4	25
188	Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer. <i>European Journal of Cancer</i> , <b>2017</b> , 78, 133-138	7.5	24
187	Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. <i>Gynecologic Oncology</i> , <b>2015</b> , 136, 37-42	4.9	24
186	Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). <i>Breast Cancer Research</i> , <b>2018</b> , 20, 132	8.3	24
185	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. <i>Gynecologic Oncology</i> , <b>2019</b> , 154, 531-538	4.9	23
184	Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. <i>Quality of Life Research</i> , <b>2018</b> , 27, 59-74	3.7	23



183	Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2014</b> , 24, 865-73	3.5	23
182	Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 1338-42	9.7	23
181	Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab). <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 120, 715-23	4.4	23
180	Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19 Suppl 2, S44-8	3.5	23
179	Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2010</b> , 20, 704-16	3.5	22
178	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5505-5505	2.2	22
177	Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4224-6	2.2	21
176	The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 174, 271-278	4.4	21
175	How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer. <i>BMC Cancer</i> , <b>2012</b> , 12, 320	4.8	20
174	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , <b>2004</b> , 93, 417-21	4.9	20
173	Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. <i>J Clin Oncol</i> 2013;(suppl; abstr 3). <i>Chinese Clinical Oncology</i> , <b>2014</b> , 3, 6	2.3	20
172	Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5533-5533 <sup>19</sup>		
171	Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2016</b> , 12, 323-331	1.9	19
170	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. <i>Gynecologic Oncology</i> , <b>2019</b> , 154, 29-37	4.9	18
169	Dry eyes and AIs: If you don't ask you won't find out. <i>Breast</i> , <b>2015</b> , 24, 694-8	3.6	18
168	Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 117, 167-76	4.4	18
167	Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 47154-47160	3.3	18
166	Impact of molecular profiling on overall survival of patients with advanced ovarian cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 19840-9	3.3	18

165	Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , <b>2017</b> , 145, 122-129	4.9	17
164	Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. <i>Obstetrics and Gynecology</i> , <b>2019</b> , 133, 245-254	4.9	17
163	Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. <i>Supportive Care in Cancer</i> , <b>2018</b> , 26, 4133-4142	3.9	17
162	Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. <i>BMC Cancer</i> , <b>2014</b> , 14, 993	4.8	17
161	Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3962-3973	12.9	16
160	Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity. <i>Oncology</i> , <b>2009</b> , 77, 342-8	3.6	16
159	Younger age-at-diagnosis for familial malignant testicular germ cell tumor. <i>Familial Cancer</i> , <b>2009</b> , 8, 451-6		16
158	Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 225-32	2.2	16
157	Effect of nifedipine in metastatic colon cancer with DNA mismatch repair gene defect. <i>Lancet, The</i> , <b>2001</b> , 357, 1767-8	4.0	16
156	Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. <i>Journal of Pain and Symptom Management</i> , <b>2019</b> , 58, 1023-1032	4.8	15
155	A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3013-3013	13.2	15
154	Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. <i>Cancer Research</i> , <b>2020</b> , 80, 116-125	10.1	15
153	Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIg Symptom Benefit Study (SBS). <i>Gynecologic Oncology</i> , <b>2018</b> , 148, 36-41	4.9	15
152	A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve. <i>Oncologist</i> , <b>2018</b> , 23, 203-213	5.7	15
151	A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice. <i>Journal of Patient-Reported Outcomes</i> , <b>2017</b> , 1, 5	2.6	14
150	Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. <i>Experimental Neurology</i> , <b>2011</b> , 227, 120-7	5.7	14
149	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , <b>2021</b> , 155 Suppl 1, 61-85	4	14
148	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 632-642	21.7	14

147	Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , <b>2018</b> , 151, 18-23	4.9	13
146	Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. <i>Journal of Gynecologic Oncology</i> , <b>2013</b> , 24, 359-66	4	13
145	Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study. <i>International Journal of Gynecological Cancer</i> , <b>2010</b> , 20, 75-81	3.5	13
144	Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5507-5507	2.2	13
143	Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial <b>2021</b> , 9,		13
142	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , <b>2018</b> , 2, pky023	4.6	13
141	Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study. <i>Acta Oncologica</i> , <b>2016</b> , 55, 226-33	3.2	12
140	Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , <b>2017</b> , 27, 900-906	3.5	12
139	Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3048-3048	2.2	12
138	Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. <i>European Journal of Cancer</i> , <b>2019</b> , 117, 99-106	7.5	11
137	Carboplatin dosing in ovarian cancer: problems and pitfalls. <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 1213-8	3.5	11
136	The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2011</b> , 7, 197-211	1.9	11
135	Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma. <i>Journal of Clinical Neuroscience</i> , <b>2006</b> , 13, 595-8	2.2	11
134	Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making?. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 2627-34	3.9	11
133	OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. <i>Gynecologic Oncology</i> , <b>2019</b> , 155, 126-134	4.9	10
132	What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. <i>Cancer</i> , <b>2017</b> , 123, 985-993	6.4	10
131	A specialist breast care nurse role for women with metastatic breast cancer: enhancing supportive care. <i>Oncology Nursing Forum</i> , <b>2011</b> , 38, 627-31	1.7	10
130	Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 11024-11024	2.2	10

129	A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS5632-TPS5632	2.2	10
128	A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 48-48	2.2	10
127	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. <i>Journal of Gynecologic Oncology</i> , <b>2019</b> , 30, e86	4	10
126	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With or Mutations. <i>JNCI Cancer Spectrum</i> , <b>2018</b> , 2, pky078	4.6	10
125	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for and Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 368-378	4	9
124	Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. <i>Gynecologic Oncology</i> , <b>2018</b> , 150, 527-533	4.9	9
123	Primary surgical management with tailored adjuvant radiation for stage IB2 cervical cancer. <i>Obstetrics and Gynecology</i> , <b>2013</b> , 121, 765-772	4.9	9
122	A fibroid or cancer? A rare case of mixed choriocarcinoma and epithelioid trophoblastic tumour. <i>Case Reports in Obstetrics and Gynecology</i> , <b>2013</b> , 2013, 492754	0.8	9
121	Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. <i>International Journal of Cancer</i> , <b>2008</b> , 123, 258-263	7.5	9
120	Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 279-285	8.7	9
119	Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysis. <i>Journal of Geriatric Oncology</i> , <b>2020</b> , 11, 508-514	3.6	9
118	Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e553-4; author reply e555-6	2.2	8
117	Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5501-5501	2.2	8
116	Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5506-5506	2.2	8
115	Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2011809	10.4	8
114	Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC). <i>Breast Cancer Research</i> , <b>2019</b> , 21, 128	8.3	8
113	Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. <i>International Journal of Gynecological Cancer</i> , <b>2010</b> , 20, 1290-8	3.5	7
112	PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5524-5524	2.2	7

111	Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy-a randomised controlled trial. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 1103-1110	3.9	7
110	When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 159, 179-186	4.9	6
109	A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer. <i>Journal of Gynecologic Oncology</i> , <b>2018</b> , 29, e81	4	6
108	Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. <i>Gynecologic Oncology</i> , <b>2005</b> , 97, 16-25	4.9	6
107	Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. <i>Cancer</i> , <b>2021</b> , 127, 2432-2441	6.4	6
106	Neoadjuvant chemoradiation (modified Eilber protocol) versus adjuvant radiotherapy in the treatment of extremity soft tissue sarcoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2016</b> , 60, 539-44	1.7	6
105	The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. <i>Journal of Cancer Survivorship</i> , <b>2021</b> , 1	5.1	6
104	Medicare-funded cancer genetic tests: a note of caution. <i>Medical Journal of Australia</i> , <b>2018</b> , 209, 193-196	4	6
103	A healthy lifestyle and survival among women with ovarian cancer. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 3361-3369	7.5	5
102	A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1239-1242	3.5	5
101	AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer. Overall survival (OS) results.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5518-5518	2.2	5
100	Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 370-379	7.5	4
99	No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers. <i>Gynecologic Oncology</i> , <b>2004</b> , 95, 430-6	4.9	4
98	Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5542-5542	2.2	4
97	Phase II study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial. ANZGOG 0903.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5520-5520	2.2	4
96	Where have we gone wrong? Phase II trials (Ph2t) do not inform the results of phase III trials (Ph3t) in platinum resistant ovarian cancer (PROC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5559-5559	2.2	4
95	The hidden burden of anxiety and depression in ovarian cancer: A prospective longitudinal study from diagnosis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 10081-10081	2.2	4
94	Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 6068-6068	2.2	4



93	Insomnia and its association with quality of life in women with ovarian cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 158, 760-768	4.9	4
92	REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2021</b> , 161, 374-381	4.9	4
91	Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2018</b> , 14, 459-464	1.9	4
90	A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. <i>Gynecologic Oncology</i> , <b>2021</b> , 163, 72-78	4.9	4
89	Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians. <i>Cancer Prevention Research</i> , <b>2021</b> , 14, 131-144	3.2	3
88	Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5081-5087	2.2	3
87	PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS5614-TPS5614	2.2	3
86	TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 9571-9571	2.2	3
85	Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5539-5539	2.2	3
84	Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians. <i>JNCI Cancer Spectrum</i> , <b>2021</b> , 5, pkaa110	4.6	3
83	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. <i>European Journal of Cancer</i> , <b>2020</b> , 139, 59-67	7.5	3
82	Relevance of Platinum-free Interval and Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g Advanced Breast Cancer (BROCADE3 Crossover). <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4983-4993	12.9	3
81	Do all patients with recurrent ovarian cancer need systemic therapy?. <i>Cancer</i> , <b>2019</b> , 125 Suppl 24, 4602-4608	4.4	3
80	Pre- and Post-Diagnosis Diet Quality and Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 229-232	4	3
79	Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. <i>Oncologist</i> , <b>2021</b> , 26, 366-374	5.7	3
78	Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	3
77	Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , <b>2018</b> , 10, 1758835918788500	5.4	2
76	Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy. <i>Clinical Colorectal Cancer</i> , <b>2007</b> , 6, 578-82	3.8	2



75	Prostate screening uptake in Australian BRCA1 and BRCA2 carriers. <i>Hereditary Cancer in Clinical Practice</i> , <b>2007</b> , 5, 161-3	2.3	2
74	Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas. <i>Pathology</i> , <b>2006</b> , 38, 145-51	1.6	2
73	Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin. <i>Cancer Investigation</i> , <b>1999</b> , 17, 479-85	2.1	2
72	Optimally debulked stage III ovarian cancer: intraperitoneal or intravenous chemotherapy?. <i>International Journal of Gynecological Cancer</i> , <b>2010</b> , 20, S20-3	3.5	2
71	392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study <b>2020</b> ,		2
70	Predictors of resilience in women treated for breast cancer: A prospective study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 9044-9044	2.2	2
69	A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS5116-TPS5116	2.2	2
68	Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5547-5547	2.2	2
67	Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS1102-TPS1102	2.2	2
66	A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3066-3066	2.2	2
65	Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 10062-10062	2.2	2
64	Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel. <i>Scientific Reports</i> , <b>2021</b> , 11, 22884	4.9	2
63	The validity of progression-free survival 2 as a surrogate trial end point for overall survival.. <i>Cancer</i> , <b>2022</b> ,	6.4	2
62	The Ovarian cancer Prognosis And Lifestyle (OPAL) study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 88-88	2.2	2
61	Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 6014-6014	2.2	2
60	Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 695-704	4.9	2
59	Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA5503-LBA5503	2.2	2
58	Identification of a Locus Near Associated With Progression-Free Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 1669-1680	4	2

57	Bilateral Salpingo-oophorectomy and Breast Cancer Risk for and Mutation Carriers: Assessing the Evidence. <i>Cancer Prevention Research</i> , <b>2021</b> , 14, 983-994	3.2	2
56	Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. <i>European Journal of Cancer</i> , <b>2021</b> , 154, 35-45	7.5	2
55	Resisting RECIST-Uniformity Versus Clinical Validity. <i>International Journal of Gynecological Cancer</i> , <b>2017</b> , 27, 1619-1627	3.5	1
54	Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and U.K. phase I/II trials.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4531-4531	2.2	1
53	Molecular profiling of clear cell ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5516-5516	2.2	1
52	Characterization of ovarian cancer long-term responders on olaparib.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5534-5534	2.2	1
51	Risk of uterine cancer in BRCA1 and BRCA2 mutation carriers.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1529-1529	2.2	1
50	Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5575-5575	2.2	1
49	Inter and intra-observer variability with the assessment of RECIST in ovarian cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5555-5555	2.2	1
48	Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 445-445	2.2	1
47	Veliparib (V) monotherapy (monoTx) following combination therapy with V + carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1091-1091	2.2	1
46	Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1097-1097	2.2	1
45	PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 6077-6077	2.2	1
44	The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS5627-TPS5627	2.2	1
43	Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting. <i>European Journal of Cancer</i> , <b>2021</b> , 148, 251-259	7.5	1
42	Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 265-276	8.7	1
41	Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIg symptom benefit committee. <i>Gynecologic Oncology</i> , <b>2021</b> , 161, 502-507	4.9	1
40	Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. <i>BMC Medical Ethics</i> , <b>2016</b> , 17, 63	2.9	1

39	Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 418-422	9.7	1
38	The value of participating in clinical trials: the whole is greater than the sum of its parts. <i>Medical Journal of Australia</i> , <b>2018</b> , 209, 424-425	4	1
37	Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. <i>Gynecologic Oncology</i> , <b>2021</b> , 163, 41-49	4.9	1
36	Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. <i>Gynecologic Oncology</i> , <b>2021</b> , 162, 375-381	4.9	1
35	Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment. <i>Gynecologic Oncology</i> , <b>2021</b> , 163, 398-407	4.9	1
34	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , <b>2021</b> , 154, 190-200	7.5	1
33	Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer <b>2017</b> , 1-27		0
32	The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9602-9602	2.2	0
31	The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?. <i>Cancer Management and Research</i> , <b>2021</b> , 13, 8457-8471	3.6	0
30	Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline / mutations and hormone receptor status from the phase-3 BROCADE3 trial.. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17562350211050601	5.4	0
29	Characterization and predictors of long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5556-5556	2.2	0
28	REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 10097-10097	2.2	0
27	Measuring subjective improvement of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/ GCIG/PoCoG).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS5615-TPS5615	2.2	0
26	Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 5584-5584	2.2	0
25	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk.. <i>JNCI Cancer Spectrum</i> , <b>2021</b> , 5, pkab090	4.6	0
24	Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , <b>2022</b> , 170, 169-178	7.5	0
23	Nonepithelial Ovarian Malignancies <b>2017</b> , 1-17		
22	Tumour profiling for treatment of patients with ovarian cancers. <i>Pathology</i> , <b>2018</b> , 50, S77	1.6	

- 21 Reply to M.G. McNamara et al and M.S. Copur et al. *Journal of Clinical Oncology*, **2015**, 33, 2583-4 2.2
- 20 A response to the forgotten fallopian tube. *Nature Reviews Cancer*, **2011**, 11, 227-227 31.3
- 19 CURRENT GENITOURINARY CANCER SURGERY. *Australian and New Zealand Journal of Medicine*, **1991**, 21, 492-492
- 18 Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation.. *Cancer Treatment and Research Communications*, **2022**, 30, 100504 2
- 17 P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).. *Journal of Clinical Oncology*, **2018**, 36, TPS574-TPS574 2.2
- 16 The hidden burden of anxiety and depression in ovarian cancer: A prospective study from diagnosis.. *Journal of Clinical Oncology*, **2018**, 36, 155-155 2.2
- 15 When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer.. *Journal of Clinical Oncology*, **2018**, 36, 172-172 2.2
- 14 P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).. *Journal of Clinical Oncology*, **2018**, 36, TPS4596-TPS4596 2.2
- 13 Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.. *Journal of Clinical Oncology*, **2018**, 36, 5568-5568 2.2
- 12 How long have we got? The accuracy of physicians' estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).. *Journal of Clinical Oncology*, **2019**, 37, 5549-5549 2.2
- 11 The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.. *Journal of Clinical Oncology*, **2014**, 32, TPS5621-TPS5621 2.2
- 10 Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial.. *Journal of Clinical Oncology*, **2016**, 34, e16056-e16056 2.2
- 9 Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).. *Journal of Clinical Oncology*, **2016**, 34, 5508-5508 2.2
- 8 P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).. *Journal of Clinical Oncology*, **2017**, 35, TPS4592-TPS4592 2.2
- 7 Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had 3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).. *Journal of Clinical Oncology*, **2017**, 35, 5575-5575 2.2
- 6 Should MMT of the endometrium/ovary be treated with anthracycline instead of taxane based chemotherapy?. *Journal of Clinical Oncology*, **2017**, 35, 5563-5563 2.2
- 5 Phase I study of olaparib (O), in combination with oral cyclophosphamide (C), in patients (pts) with metastatic triple negative breast cancer (TNBC) and recurrent high grade serous ovarian cancer (OVCA).. *Journal of Clinical Oncology*, **2017**, 35, 1104-1104 2.2
- 4 Squamous Cell Carcinomas Arising From Dermoids **2011**, 131-133

- 3      Response as a Measure of Treatment Efficacy in Clinical Trials: Should RECIST Be Abandoned? **2014**, 91-100
- 2      The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer **2021**, 43-53
- 1      TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.. *Journal of Clinical Oncology*, **2022**, JCO2102108 2.2